Based on these findings, supplements of chemokines CCL11 may be a new therapeutic strategy for inducing neovascularization and improving perfusion recovery, thereby preventing the occurrence of adverse events such as disability and death in peripheral vascular diseases. This evidence concerns the gene CCL11 and peripheral vascular disease.